1.
Acta Oncol
; 59(4): 458-461, 2020 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31948319
Assuntos
Mortalidade Hospitalar/tendências , Unidades de Terapia Intensiva/estatística & dados numéricos , Neoplasias/mortalidade , Terapia Combinada , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias/patologia , Neoplasias/terapia , Prognóstico , Estudos Retrospectivos , Taxa de Sobrevida
2.
Bull Cancer
; 105(11): 1084-1093, 2018 Nov.
Artigo
em Francês
| MEDLINE
| ID: mdl-30340752
RESUMO
Looking at the results of the early trials presented at the 2018 American Society of Clinical Oncology (ASCO) conference can help identify the molecules and strategies that will potentially enter the practices of tomorrow. It is in this spirit that this subject has justified the attention of residents in oncology and the writing of this synthesis. Molecules that can represent breakthrough innovations are presented as well as new therapeutics under development acting on targets already validated in clinical practice and early data of checkpoint inhibitors in combination with different immunomodulators, as well as new strategies for immunotherapies (vaccines and cell therapy).